Laura Chico
Stock Analyst at Wedbush
(3.60)
# 857
Out of 5,005 analysts
224
Total ratings
46.1%
Success rate
7.21%
Average return
Main Sectors:
Stocks Rated by Laura Chico
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LRMR Larimar Therapeutics | Maintains: Outperform | $15 → $11 | $4.87 | +125.87% | 3 | Sep 30, 2025 | |
| PEPG PepGen | Maintains: Outperform | $9 → $8 | $5.13 | +55.95% | 12 | Sep 30, 2025 | |
| DNTH Dianthus Therapeutics | Maintains: Outperform | $42 → $44 | $34.94 | +25.93% | 9 | Sep 12, 2025 | |
| TRML Tourmaline Bio | Downgrades: Neutral | $48 | $47.90 | +0.21% | 3 | Sep 9, 2025 | |
| JBIO Jade Biosciences | Maintains: Outperform | $17 → $18 | $8.86 | +103.16% | 3 | Aug 14, 2025 | |
| SLDB Solid Biosciences | Maintains: Outperform | $17 → $14 | $5.90 | +137.29% | 3 | Aug 13, 2025 | |
| STOK Stoke Therapeutics | Maintains: Outperform | $16 → $22 | $25.56 | -13.93% | 7 | Aug 13, 2025 | |
| XENE Xenon Pharmaceuticals | Maintains: Outperform | $42 → $43 | $39.61 | +8.56% | 9 | Aug 12, 2025 | |
| TVTX Travere Therapeutics | Maintains: Outperform | $30 → $32 | $24.64 | +29.87% | 12 | Aug 7, 2025 | |
| GOSS Gossamer Bio | Maintains: Outperform | $4 → $5 | $2.57 | +94.55% | 6 | Aug 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $13 → $14 | $5.26 | +166.16% | 14 | Aug 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $137 → $141 | $137.03 | +2.90% | 10 | Jul 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $35 → $34 | $31.21 | +8.94% | 13 | Jul 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $17 | $27.11 | -37.29% | 1 | Jul 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $18 | $7.15 | +151.75% | 1 | Jun 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $130 | $130.07 | -0.05% | 1 | Jun 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $121 | $159.88 | -24.32% | 18 | Jun 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $27 | $23.39 | +15.43% | 7 | Jun 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $4 | $6.89 | -41.94% | 4 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $30 | $15.42 | +94.55% | 8 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $34 → $26 | $30.14 | -13.74% | 8 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $26 → $28 | $54.38 | -48.51% | 7 | May 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $43 | $15.65 | +174.76% | 10 | Apr 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $4 → $3 | $1.84 | +63.04% | 2 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $27 → $28 | $7.52 | +272.34% | 9 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $30 → $29 | $23.80 | +21.85% | 14 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $8 → $7 | $4.86 | +44.03% | 4 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $42 | $21.65 | +94.00% | 7 | Jul 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $13 → $11 | $0.56 | +1,847.25% | 4 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5 | $6.11 | -18.17% | 5 | Mar 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | n/a | $55.43 | - | 5 | Sep 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $5 | $4.76 | +5.04% | 2 | Aug 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $149 | $15.81 | +839.28% | 1 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $720 | $14.83 | +4,755.02% | 1 | Jan 19, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Strong Buy | $280 | $101.99 | +174.54% | 1 | Apr 21, 2017 |
Larimar Therapeutics
Sep 30, 2025
Maintains: Outperform
Price Target: $15 → $11
Current: $4.87
Upside: +125.87%
PepGen
Sep 30, 2025
Maintains: Outperform
Price Target: $9 → $8
Current: $5.13
Upside: +55.95%
Dianthus Therapeutics
Sep 12, 2025
Maintains: Outperform
Price Target: $42 → $44
Current: $34.94
Upside: +25.93%
Tourmaline Bio
Sep 9, 2025
Downgrades: Neutral
Price Target: $48
Current: $47.90
Upside: +0.21%
Jade Biosciences
Aug 14, 2025
Maintains: Outperform
Price Target: $17 → $18
Current: $8.86
Upside: +103.16%
Solid Biosciences
Aug 13, 2025
Maintains: Outperform
Price Target: $17 → $14
Current: $5.90
Upside: +137.29%
Stoke Therapeutics
Aug 13, 2025
Maintains: Outperform
Price Target: $16 → $22
Current: $25.56
Upside: -13.93%
Xenon Pharmaceuticals
Aug 12, 2025
Maintains: Outperform
Price Target: $42 → $43
Current: $39.61
Upside: +8.56%
Travere Therapeutics
Aug 7, 2025
Maintains: Outperform
Price Target: $30 → $32
Current: $24.64
Upside: +29.87%
Gossamer Bio
Aug 6, 2025
Maintains: Outperform
Price Target: $4 → $5
Current: $2.57
Upside: +94.55%
Aug 5, 2025
Maintains: Outperform
Price Target: $13 → $14
Current: $5.26
Upside: +166.16%
Jul 31, 2025
Maintains: Outperform
Price Target: $137 → $141
Current: $137.03
Upside: +2.90%
Jul 14, 2025
Maintains: Neutral
Price Target: $35 → $34
Current: $31.21
Upside: +8.94%
Jul 8, 2025
Initiates: Outperform
Price Target: $17
Current: $27.11
Upside: -37.29%
Jun 30, 2025
Maintains: Outperform
Price Target: $16 → $18
Current: $7.15
Upside: +151.75%
Jun 18, 2025
Reiterates: Neutral
Price Target: $130
Current: $130.07
Upside: -0.05%
Jun 12, 2025
Reiterates: Neutral
Price Target: $121
Current: $159.88
Upside: -24.32%
Jun 5, 2025
Reiterates: Outperform
Price Target: $27
Current: $23.39
Upside: +15.43%
May 15, 2025
Reiterates: Neutral
Price Target: $4
Current: $6.89
Upside: -41.94%
May 7, 2025
Maintains: Outperform
Price Target: $32 → $30
Current: $15.42
Upside: +94.55%
May 7, 2025
Maintains: Neutral
Price Target: $34 → $26
Current: $30.14
Upside: -13.74%
May 5, 2025
Maintains: Underperform
Price Target: $26 → $28
Current: $54.38
Upside: -48.51%
Apr 21, 2025
Maintains: Outperform
Price Target: $43
Current: $15.65
Upside: +174.76%
Mar 12, 2025
Maintains: Outperform
Price Target: $4 → $3
Current: $1.84
Upside: +63.04%
Mar 12, 2025
Maintains: Outperform
Price Target: $27 → $28
Current: $7.52
Upside: +272.34%
Mar 3, 2025
Maintains: Neutral
Price Target: $30 → $29
Current: $23.80
Upside: +21.85%
Aug 7, 2024
Maintains: Neutral
Price Target: $8 → $7
Current: $4.86
Upside: +44.03%
Jul 29, 2024
Reiterates: Outperform
Price Target: $42
Current: $21.65
Upside: +94.00%
Apr 11, 2024
Maintains: Outperform
Price Target: $13 → $11
Current: $0.56
Upside: +1,847.25%
Mar 20, 2024
Reiterates: Neutral
Price Target: $5
Current: $6.11
Upside: -18.17%
Sep 28, 2023
Initiates: Market Perform
Price Target: n/a
Current: $55.43
Upside: -
Aug 12, 2022
Maintains: Outperform
Price Target: $9 → $5
Current: $4.76
Upside: +5.04%
Aug 8, 2022
Downgrades: Neutral
Price Target: $149
Current: $15.81
Upside: +839.28%
Jan 19, 2018
Initiates: Outperform
Price Target: $720
Current: $14.83
Upside: +4,755.02%
Apr 21, 2017
Initiates: Strong Buy
Price Target: $280
Current: $101.99
Upside: +174.54%